SCHEMBL2084992

SCHEMBL2084992

Cc1cccnc1CC(CCCN)NCc1nccn1-c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 1/20 0.36
CXCR4 P61073 4/20 0.36
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ALOX15B O15296 1/20 0.32
GAA P10253 1/20 0.32
KDR P35968 1/20 0.31
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30
EGLN1 Q9GZT9 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
CHRM5 P08912 1/20 0.30
CHRM1 P11229 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4214955 0.82 CXCR4 (0.41) CXCR4CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL2083528 0.82 MAPK1 (0.36) CXCR4MEN1ALDH1A1RAB9AKMT2A
SCHEMBL2081740 0.80 CXCR4 (0.35) ADRA2CCXCR4MEN1KMT2AADORA2A
SCHEMBL2082171 0.76 ADORA2A (0.41) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL2084914 0.76 CXCR4 (0.38) CXCR4KDREGLN1ADORA2AADORA1
SCHEMBL4530202 0.75 TLR8 (0.37) ADRA2CCXCR4ALDH1A1KMT2AADORA2A
SCHEMBL2084125 0.75 ADRA2C (0.35) ADRA2CCXCR4
SCHEMBL2083908 0.75 ADORA2A (0.38) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL2085159 0.75 CXCR4 (0.38) CXCR4CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL2084233 0.74 CXCR4 (0.42) CXCR4CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US claimed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US claimed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US claimed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 ADRA2C 663/4885CXCR4 1/4885CYP1A2 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.